Circulation. Genomic and precision medicine

Long-term benefits and safety of GLP-1 receptor activators and SGLT2 blockers in the general population using genetic analysis

Updated

Abstract

Higher genetic scores for SGLT2 inhibitors are associated with a lower risk of heart failure and chronic kidney disease.

  • Higher SGLT2 inhibitor genetic instrument scores are linked to a lower risk of heart failure (odds ratio [OR], 0.97) and chronic kidney disease (OR, 0.98).
  • Higher GLP-1R agonist genetic instrument scores are associated with reduced risks of heart failure (OR, 0.97), chronic kidney disease (OR, 0.96), and coronary artery disease (OR, 0.98).
  • No associations were found between the GLP-1R agonist genetic instrument and multiple endocrine neoplasia or medullary thyroid carcinoma.
  • A Phenome-Wide Association Study identified lower diabetes risk linked to SGLT2 inhibitor and GLP-1R agonist genetic instruments, but no other phenotypes were associated.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free